TrialESMO open2024

A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A.

A Mouri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.